Edition:
United Kingdom

People: ContraVir Pharmaceuticals Inc (CTRV.OQ)

CTRV.OQ on NASDAQ Stock Exchange Capital Market

0.11USD
22 May 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$0.11
Open
$0.12
Day's High
$0.12
Day's Low
$0.11
Volume
746,227
Avg. Vol
623,277
52-wk High
$2.56
52-wk Low
$0.10

Lippa, Arnold 

Dr. Arnold S. Lippa, Ph.D., is Independent Director of the Company. Dr. Lippa has been Executive Chairman of the Board of RespireRx Pharmaceuticals Inc., since March 2013, and was appointed Chief Scientific Officer in August 2015. Previously, he served as Chief Executive Officer and President. He is also Chairman of the Board of Xintria Pharmaceutical Corporation, which he co-founded in 2006. Dr. Lippa is a Managing Member and founder of T Morgen Capital LLC, which is an investment and management company specializing in the creation and management of biomedical companies. Since 2005, T Morgen Capital has been a significant equity owner and a managing member of Aurora Capital LLC, a life science focused FINRA member firm, where Dr. Lippa represents T Morgen Capital as a Manager. In 2004, Dr. Lippa co-founded and currently is representing T Morgen Capital, a Managing Member, as a Manager of Atypical BioCapital Management LLC and Atypical BioVentures Fund LLC, a life science fund management company and fund, respectively, both of which are affiliates of Aurora Capital. Dr. Lippa was a founder of DOV Pharmaceutical, Inc., and served as Chairman of the Board and Chief Executive Officer from its inception in April 1995 until 2005. Prior to DOV, Dr. Lippa co-founded and co-managed a number of life sciences companies, including Praxis Pharmaceuticals, Inc., which he co-founded and took public in 1985, serving as President and Chief Operating Officer from 1984 until 1987. Dr. Lippa’s experience as a biotechnology company executive and a financier qualifies him to be a director of our Company.

Basic Compensation

Total Annual Compensation, USD 55,125
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 22,530
Fiscal Year Total, USD 77,655

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --